Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Canaccord Genuity Reiterates Buy Rating on Beachbody Company (BODI)
-
Canaccord Genuity Reiterates Zeta Global (ZETA) at Buy, 'continue to be buyers of ZETA shares'
-
Form 8.3 - [IDOX PLC - 13 01 2026] - (CGWL)
-
Form 8.3 - [JTC PLC - 13 01 2026] - (CGAML)
-
Net Asset Value(s)
-
Canaccord Genuity Starts Gatekeeper Systems (GSI:CN) at Spec. Buy
-
Canaccord Genuity Upgrades Lovisa Holdings Ltd (LOV:AU) to Buy
-
Canaccord Genuity Reiterates Buy Rating on Planet Fitness (PLNT)
-
Canaccord Genuity Reiterates Buy Rating on Omada Health Inc (OMDA)
-
Canaccord Genuity Reiterates Hold Rating on Caris Life Sciences Inc (CAI)
-
Canaccord Genuity Reiterates Buy Rating on AxoGen, Inc. (AXGN)
-
Canaccord Genuity Reiterates Buy Rating on Biodesix (BDSX)
-
Canaccord Genuity Reiterates Buy Rating on GRAIL, Inc. (GRAL)
-
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hold
-
Canaccord Genuity Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
Form 8.3 - [JTC PLC - 12 01 2026] - (CGAML)
-
Valeura Energy Inc. Announces Q4 2025 Update and 2026 Guidance
-
Thor Explorations Announces Strong Q4 2025 Gold Production of 23,604 Ounces, 2026 Operating Guidance and Bonus Q4 Dividend
-
Generac Holdings (GNRC) PT Lowered to $236 at Canaccord Genuity
-
Canaccord on Alphatec Holdings (ATEC): 'Beat not as robust vs prior Qs, but conservative FY26 guide set'
-
Net Asset Value(s)
-
BitGo aims to raise over $200 million in U.S. IPO
-
BitGo launches IPO of 11.8 million shares priced at $15-17 each
-
BitGo Holdings Announces Launch of Initial Public Offering
-
Leeds Equity Partners Continues Expansion of Team Amid Firm Growth
-
Form 8.3 - [IDOX PLC - 09 01 2026] - (CGWL)
-
Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)
-
Canaccord Genuity Reiterates Buy Rating on Exagen (XGN)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Could the S&P 500 post a fourth straight year of gains?
-
Oroco files prospectus for C$20 million public offering
-
Oroco Files Prospectus Supplement in Connection with Bought Deal Public Offering
-
Form 8.3 - [IDOX PLC - 08 01 2026] - (CGWL)
-
Helen of Troy (HELE) PT Lowered to $22 at Canaccord Genuity
-
Globus Medical (GMED) PT Raised to $112 at Canaccord Genuity
-
Canaccord on Quanterix Corp. (QTRX): 'we remain on the sidelines until further clarity'
-
Aurelion establishes $500 million at-the-market equity offering program
-
Aurelion Inc. (NASDAQ: AURE) Enters into Sales Agreement for At-The-Market Offering
-
Form 8.3 - [IDOX PLC - 07 01 2026] - (CGWL)
-
Form 8.3 - [IDOX PLC - 07 01 2026] - (CGAML)
-
Withdrawal of Letter of Intent - IDOX plc - 08 01 2026 - (CGAML)
-
Canopy Growth completes C$425 million recapitalization deal
-
Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy
-
Canaccord Genuity Downgrades Ventyx Biosciences Inc (VTYX) to Hold
-
Gold Production for YE 2025 and Award of Impact Benefit Agreement (“IBA”)
-
Gold Production for YE 2025 and Award of Impact Benefit Agreement (“IBA”)
-
ReconAfrica Announces Upsize of Underwritten Offering to C$32.0 Million to Advance Multi-Zone Production Testing at Kavango West 1X, Accelerate Follow-on Appraisal Drilling on Kavango Discovery and Ad
-
Oroco Announces Upsize of Bought Deal Financing Led by Canaccord Genuity
-
Alphabet (GOOGL) PT Raised to $390 at Canaccord Genuity
-
Partial Withdrawal of Letter of Intent - IDOX plc - 07 01 2026 - (CGAML)
